La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that it will present data from its March 2007 interim antibody analysis on Riquent® (abetimus sodium), its drug candidate for...
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, will present on Tuesday, September 18, at 11:45 a.m....
La Jolla Pharmaceutical Company (Nasdaq:LJPC) reported a net loss for the three months ended June 30, 2007 of $13.5 million, or $0.34 per share (on 39.3 million weighted-average shares),...
La Jolla Pharmaceutical to Present at Pacific Growth Equities Life Sciences Conference
SAN DIEGO - PRNewswire-FirstCall - June 2
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- La Jolla...